To include your compound in the COVID-19 Resource Center, submit it here.

Recombinant C1 inhibitor: Began Phase I trial

Pharming Group N.V. (EASD:PHAR; AEX:PHAR), Leiden, the Netherlands

Read the full 80 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE